| human | Q5 |
| P6178 | Dimensions author ID | 0770112623.60 |
| P108 | employer | University of Texas Medical Branch | Q921264 |
| P735 | given name | Joan | Q16652258 |
| Joan | Q16652258 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q34292954 | A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge |
| Q91006409 | A Lethal Aerosol Exposure Model of Nipah Virus Strain Bangladesh in African Green Monkeys |
| Q36043219 | A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs |
| Q64360457 | A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates |
| Q90162766 | A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge |
| Q35855727 | A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge |
| Q34120677 | A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment |
| Q37713970 | A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge |
| Q34220503 | Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates |
| Q91006452 | An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys |
| Q38378926 | An Outbreak of Ebola Virus Disease in the Lassa Fever Zone |
| Q38956790 | Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection |
| Q45758605 | Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants |
| Q39138259 | Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo |
| Q64063045 | Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants |
| Q40314624 | CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates |
| Q45391085 | Cellular immune response to Marburg virus infection in cynomolgus macaques |
| Q34223117 | Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. |
| Q36043232 | Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model |
| Q40561759 | Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. |
| Q98459096 | Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys |
| Q34566171 | Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine |
| Q40526223 | Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques |
| Q28607807 | Development of Prototype Filovirus Recombinant Antigen Immunoassays |
| Q21563440 | Development of a new vaccine for the prevention of Lassa fever |
| Q33587327 | Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection |
| Q21559476 | Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates |
| Q40433072 | Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates |
| Q21131616 | Effective post-exposure treatment of Ebola infection |
| Q59357446 | Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates |
| Q95602120 | Establishment of an African green monkey model for COVID-19 |
| Q102379526 | Establishment of an African green monkey model for COVID-19 and protection against re-infection |
| Q44089771 | Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections |
| Q40588105 | Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections |
| Q38913439 | Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection |
| Q40824502 | Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies |
| Q37072349 | Framework for leadership and training of Biosafety Level 4 laboratory workers |
| Q40040779 | Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever |
| Q89811064 | Immune correlates of postexposure vaccine protection against Marburg virus |
| Q28768041 | Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs |
| Q40433110 | In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein |
| Q33850032 | Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses |
| Q38603013 | Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants. |
| Q36936330 | Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever |
| Q98564398 | Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase |
| Q98578423 | Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase |
| Q24290732 | Lassa fever in post-conflict sierra leone |
| Q34473079 | Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates |
| Q33987611 | Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses |
| Q40433113 | Lymphocyte death in a mouse model of Ebola virus infection |
| Q40433085 | Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. |
| Q35852525 | Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. |
| Q34098909 | Marburg virus vaccines: comparing classical and new approaches |
| Q38868057 | Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig. |
| Q36831453 | Monoclonal antibody therapy for Junin virus infection |
| Q28602816 | Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits |
| Q24701722 | Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak |
| Q33269796 | Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys |
| Q37310749 | Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus |
| Q40091054 | Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates |
| Q40674927 | Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses |
| Q35843254 | Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection |
| Q35014564 | Pathogenesis of Lassa fever in cynomolgus macaques |
| Q40309258 | Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques |
| Q37147843 | Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy |
| Q40433105 | Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus |
| Q40647548 | Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. |
| Q59358208 | Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates |
| Q34519791 | Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment |
| Q34526756 | Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference |
| Q34022606 | Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study |
| Q35877126 | Postexposure treatment of Marburg virus infection |
| Q37558780 | Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers |
| Q97905075 | Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment |
| Q37520171 | Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. |
| Q35784923 | Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates |
| Q91839729 | Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death |
| Q35076828 | Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge |
| Q40433076 | Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever |
| Q21090120 | Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates |
| Q34589949 | Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates |
| Q28396399 | Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA |
| Q89545408 | Resistance of Cynomolgus Monkeys to Nipah and Hendra Virus Disease Is Associated With Cell-Mediated and Humoral Immunity |
| Q59358207 | Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms |
| Q44106241 | Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge |
| Q35300062 | Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus |
| Q36239796 | Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus |
| Q34606818 | Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus |
| Q37118389 | The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus |
| Q36146469 | The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset |
| Q40062330 | Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. |
| Q35741723 | Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody |
| Q39696796 | Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation |
| Q33981963 | Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus |
| Q44106136 | Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis |
| Q34370420 | Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory |
| Q33974706 | Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys |
| Q40092356 | Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies |
| Q64994229 | Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease. |
| Q36043290 | Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus |
| Q34120895 | Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates |
| Q21131585 | Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates |
| Q30724121 | Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus |
| Q34598925 | Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses |
| Q45325246 | siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease |
Search more.